$56.99
0.00%
Nasdaq, Thu, Sep 05 2024
ISIN
US61775R1059
Symbol
MORF
Sector
Industry

Key metrics

Market capitalization $2.86b
Enterprise Value $2.24b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.62
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-213.02m
Free Cash Flow (TTM) Free Cash Flow $-137.65m
Cash position $628.37m
EPS (TTM) EPS $-3.60
P/S forward 2,862.31
EV/Sales forward 2,237.26
Short interest 7.55%
Show more

Is Morphic Holding Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Morphic Holding Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Morphic Holding Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Morphic Holding Inc forecast:

Buy
50%
Hold
50%

Financial data from Morphic Holding Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.12 1.12
10% 10%
-
-1.12 -1.12
115% 115%
-
- Selling and Administrative Expenses 46 46
35% 35%
-
- Research and Development Expense 165 165
43% 43%
-
-212 -212
50% 50%
-
- Depreciation and Amortization 1.12 1.12
10% 10%
-
EBIT (Operating Income) EBIT -213 -213
49% 49%
-
Net Profit -180 -180
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Morphic Holding Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Morphic Holding Inc Stock News

Neutral
PRNewsWire
about one month ago
Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MOR...
Neutral
Accesswire
about 2 months ago
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgand...
Neutral
Accesswire
about 2 months ago
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE:LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg....
More Morphic Holding Inc News

Company Profile

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Head office United States
CEO Praveen Tipirneni
Employees 121
Founded 2014

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today